Emergence Delirium, Postoperative Pain
Conditions
Keywords
Parecoxib;, emergence delirium;, postoperative pain;, elderly patients;, abdominal surgery, Parecoxib on emergence agitation and postoperative pain
Brief summary
This prospective, double blind, placebo-controlled, parallel group study will be conducted in three study centers in Guangzhou, China. Patients aged older than 65 (ASA I-III) undergoing primary elective abdominal surgery with general anesthesia will be involved in this study. According to previous studies and our pilot trial, the sample size was estimated to be 900 subjects (each center recruiting 300 patients). All eligible patients will be randomly assigned to one of two groups: study group receiving parecoxib and control group receiving normal saline. All patients will be managed with by a standard clinical anesthesia protocol with a sevoflurane-based general anesthesia with continuous intravenous remifentanil, followed by a postoperative PCA with morphine. The emergence delirium will be evaluated by two persons blinding to medication and grouping using Riker sedation-agitation scale immediately since tracheal extubation and at specific time points until patients being discharged from PACU. Pain intensity assessments and pain relief assessments will also be conducted by the patients at given time points in 2 days postoperatively. The morphine-sparing effect, tolerability and safety of parecoxib will be investigated as well.
Detailed description
The inclusion criteria of this study includes: * Aged older than 65; * Primary elective abdominal surgery under general anesthesia; * Ability to understand how to use pain assessment scales and PCA device. The outcome measures of this study includes: * Emergence Delirium Assessment; * Pain intensity and pain relief efficacy endpoints; * Tolerability and Safety Assessments
Interventions
DRUGParecoxib
The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
Sponsors
Pfizer
First Affiliated Hospital, Sun Yat-Sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Aged older than 65; * Body weight of at least 50 kg; * Primary elective abdominal surgery under general anesthesia; * Preoperative health graded as class ASA I-III, based on medical history and physical examination; * Ability to understand how to use pain assessment scales and PCA device
Exclusion criteria
* Emergency or revised abdominal surgery; * History of known use of analgesics or any other agent that could interfere with analgesic responses during the up to 24 h before receipt of the study medication which including NSAIDs, tricyclic antidepressants, neuroleptic or antipsychotic agents, or corticosteroids (except routine preoperative medication); * History of known or suspected drug abuse; * Known allergy, sensitivity, or contraindication to opioid and non-opioid analgesic drugs; * History of bleeding disorders, peptic ulceration, or anticoagulant use within the past month; * History of asthma or bronchospasm; * History of inflammatory bowel disease, a chronic or acute renal or hepatic disorder, coronary heart disease; * History of dementia and psychological disorder; * Contraindication to parecoxib.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| emergence agitation | 45 min after anesthesia | the incidence of emergence agitation after recovery from general anesthesia before discharging from PACU |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The amount of morphine consumption and Pain intensity | 48h postoperatively | The amount of morphine consumption from PCA pump at PACU, 12, 24, 36, and 48h after first dose of study medication; Pain intensity (NRS scores) at 2, 4, 6, 9, 12, 18, 24, 36 and 48 h after the first dose of study medication. |
Countries
China
Contacts
Primary ContactHaihua Shu, MD; Ph D
Backup ContactWenqi Huang, MD
Outcome results
None listed